Mode
Text Size
Log in / Sign up
N/A N=2,591 Randomized Single-blind Prevention

Project RESIST: Evaluating the Effects of Anti-smoking Inoculation Messages Among Young Adult Sexual Minority Women

Cigarette Smoking Behavior

Enrolled (actual)
2,591
Serious AEs
0.0%
Results posted
Jul 2024
Primary outcome: Primary: Intention to Quit Smoking at Follow-up — 11.8; 11.0; 14.4; 9.9 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Culturally Tailored Anti-Smoking Messages (Other)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Abramson Cancer Center at Penn Medicine
Primary completion
Jul 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Intention to Quit Smoking at Follow-up
11.8; 11.0; 14.4; 9.9; 11.1; 14.4
PRIMARY
Intention to Purchase Cigarettes
5.5; 5.7; 4.2; 5.9; 5.7; 3.9
PRIMARY
Susceptibility to Smoke Cigarettes
3.0; 2.7; 2.2; 2.8; 2.5; 3.0
SECONDARY
Receptivity to Marketing
6.3; 6.1; 6.4; 6.6; 6.8; 6.5
SECONDARY
Tobacco Industry Attitudes
8.1; 8.2; 7.8; 7.6; 7.1; 7.4
SECONDARY
Tobacco Industry Beliefs
11.7; 11.7; 10.9; 11.1; 10.4; 11.0

Summary

Project RESIST is an R01 study funded by NCI focused on determining the effects of using culturally tailored inoculation approaches to increase resilience to tobacco marketing influences among young adult sexual minority women ages 18-30 and incorporates critical stakeholder inputs that support later adoption and implementation. The study team is utilizing formative research to design and pre-test anti-smoking messages and two national longitudinal online survey experiments.

Eligibility Criteria

Inclusion Criteria

  • Ages 18-30
  • Woman
  • Identifies as a sexual minority (any sexual orientation other than heterosexual)
  • Lives in the United States
  • Able to take surveys in English

Exclusion Criteria

  • Under 18 or older than 30
  • Men
  • Heterosexual
  • Lives outside the United States
  • Unable to take the survey in English
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05499520). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search